Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 11 2020 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late
clinical-stage biopharmaceutical company working to develop the
first FDA-approved ophthalmic formulation of bevacizumab for use in
retinal indications, announced today that it has received
notification from Nasdaq that it has regained compliance with the
minimum bid price for continued listing on the Nasdaq Capital
Market, as the closing bid price of the Company’s common stock has
been at $1.00 or greater for 10 consecutive trading days.
Accordingly, this matter is now closed.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage
biopharmaceutical company working to develop the first FDA-approved
ophthalmic formulation of bevacizumab for use in retinal
indications, including wet AMD, DME and BRVO. If ONS-5010 /
LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic
formulation of bevacizumab, is approved, Outlook Therapeutics
expects to commercialize it as the first and only approved
ophthalmic formulation of bevacizumab for use in treating approved
retinal diseases in the United States, Europe, Japan and other
markets. Outlook Therapeutics expects to file ONS-5010 with the
U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For
more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Outlook Therapeutics: Lawrence A. Kenyon
LawrenceKenyon@outlooktherapeutics.com
Investor Inquiries: Jenene Thomas Chief
Executive Officer JTC Team, LLC T:
833.475.8247 OTLK@jtcir.com
Media Inquiries:Emmie TwomblyMedia Relations
SpecialistLaVoie Health ScienceM:
857.389.6042etwombly@lavoiehealthscience.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Sep 2023 to Sep 2024